Vesilute 20mg

What is Vesilute?

Vesilute is a synthetic bioactive peptide belonging to the Havensone peptide family, featuring a core amino acid sequence of Glu-Asp. It exerts regulatory effects on urinary system tissues like the bladder and prostate by influencing cellular gene expression to modulate physiological functions in these tissues.

Vesilute Structure

Source: PubChem

Sequence: ED

Molecular Formula: C9H14N2O7

Molecular Weight: 262.22 g/mol

CAS Number: 3918-84-1

PubChem CID：99716

Synonyms: alpha-Glutamylaspartic acid

Ovagen Research

What is the research background of Vesilute?

In the exploration of bioactive substances, peptides have garnered significant attention due to their pivotal roles in numerous physiological processes. Vesilute, a synthetic bioactive peptide belonging to the Havensone peptide family, features a core amino acid sequence of Glu-Asp. Initial research on Vesilute was extremely limited. However, given its structural similarity to Prostamax—another Glu-Asp sequence-containing peptide in the same family—scientists hypothesized that it might possess analogous tissue-modulating functions, thereby initiating a journey of in-depth investigation.

Urinary system disorders, such as chronic cystitis and benign prostatic hyperplasia, significantly impair quality of life, particularly among the elderly. Vesilute was discovered to exert unique regulatory effects on bladder and prostate tissues. Subsequent research gradually revealed that it may influence chronic sterile inflammation in prostate tissue by affecting gene expression at the cellular level. It modulates key inflammatory indicators such as tissue swelling, congestion, and cellular infiltration, offering a novel approach to addressing urological challenges.

What are the application studies of Vesilute?

Targeted Regulation Research for Urinary System Diseases

As a bioactive regulatory peptide within the Havensone family, Vesilute holds a central position in urinary system disease research. Its studies focus on age-related conditions like chronic cystitis and benign prostatic hyperplasia (BPH), improving prostate microcirculation and inhibiting abnormal cell proliferation. It reduces prostate tissue swelling and congestion, decreases inflammatory cell infiltration, and alleviates urinary dysfunction symptoms like frequent urination and urgency. This organ-specific regulatory effect may relate to epigenetic control and chromosomal density alterations—a shared cellular mechanism among Havensone peptides—facilitating non-pharmaceutical interventions for degenerative urological diseases.

Expanded Exploration in Fertility and Smooth Muscle Function

Vesilute demonstrates cross-tissue physiological regulatory potential. In reproductive health, Russian studies indicate it enhances sperm production, motility, and normal morphology ratios, improving fertility potential by optimizing the germ cell microenvironment. Its anti-aggregatory effects on bladder smooth muscle are progressively revealed, potentially influencing smooth muscle contractility by regulating glycogen metabolism-related enzyme activity—offering new insights into the molecular mechanisms of bladder dysmotility.

Conclusion

As a bioactive regulatory peptide within the Havensone family, Vesilute demonstrates multifaceted application research with clear value. At the core application level, it demonstrates outstanding efficacy in intervening urinary system disorders. By regulating prostate microcirculation and suppressing inflammatory responses, it alleviates tissue swelling, congestion, and urinary dysfunction caused by chronic cystitis and benign prostatic hyperplasia, offering a potential non-pharmaceutical intervention approach for age-related degenerative urinary diseases prevalent in the elderly. In reproductive health, it optimizes sperm yield, motility, and morphology ratios, offering new pathways for fertility enhancement research. Its regulatory effects on bladder smooth muscle function also provide insights into bladder dysmotility mechanisms.

By addressing unmet needs in urology and reproductive health, Vesilute fills gaps in disease intervention, laying foundations for developing safe, targeted regulatory solutions. It enriches understanding of the biological regulatory mechanisms within the Havensone peptide family, advancing research depth in organ-specific regulation and cross-system physiological control of peptide substances. This provides crucial theoretical and experimental foundations for subsequent peptide biopharmaceutical development, playing a significant role.

About The Author

The above-mentioned materials are all researched, edited and compiled by Corevia Peptides.